OssDsign: Analyst - ABG

Q4'23 results due 6 February
Already pre-announced strong sales for Oct-Nov
Fully focused US orthobiologics company as of New Year


Q4'23 expectations

We forecast Q4 sales of SEK 33.5m, up 68% y-o-y from SEK 19.9m in Q4'22. OssDsign has already pre-announced sales for Oct-Nov (Dec 6, 2023) of SEK 25.2m, implying sales of SEK 9m in December in our Q4'23 forecast. The expected strong sales growth in Q4 is expected to have been driven by >230% sales growth for the Catalyst (orthobiologics) product to SEK 25m, from SEK 7.5m in Q4'22. We forecast Q4 adj. EBIT of -16.9m, excluding non-recurring items of SEK 15m related to the discontinuation of the CMF business during Q4'23.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossdsign/Equity-research/2024/1/ossdsign---analyst/